Two DNMT inhibitors, 5-azacytidine and 5-aza-2′-deoxycytidine, have indeed been approved by the US Food and Drug Administration (FDA) for the treatment of myelodysplastic syndromes and acute myeloid leukemia [96]. The gene discussed is DNMT1; the disease is acute myeloid leukemia.